Table 16.

Incidence of all-grade hematological adverse events in cancer patients treated with ICI [71, 101]

Drugs/irAE	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined treatment
Hematological toxicity	<1% [71]	NR	NR
Anemia	3.2% [101]	NR	3.9% [101]

NR not reported